Date: 2015-09-09
Type of information: Series C financing round
Company: Biom’Up (France)
Investors: Gimv (Belgium) Bpifrance Large Venture (France) Lundbeckfond Ventures (Denmark) InnoBio (France) Sham Innovation Santé (France) ACG Management (France) Sofimac (France) Mérieux Développement (France) OTC AM (France) Euroainvest (France) l’Améliane (France) company’s management team
Amount: €31,3 million
Funding type: series C financing round
Planned used: Biom\'Up, a specialist in collagen-based absorbable medical devices for biosurgery, is developing a new generation hemostatic product, Hemoblast™, and markets its proprietary products Cova™, Covamesh™ and Matri™Bone. The proceeds of the capital increase will be primarily used to finance further development of Hemoblast™, particularly in the context of its clinical study conducted in Europe and North America. The company achieved a turnover of more than €3 million in 2014 and expects more than 30% growth in sales of its existing product portfolio for 2015.
Others: * On September 9, 2015, Biom’Up announced that the company has secured € 31,3 million in a Series C financing round from an investment syndicate consisting of Gimv, Bpifrance Large Venture and Lundbeckfond Ventures, alongside its existing shareholders (InnoBio, Sham Innovation Santé, ACG Management, Sofimac, Mérieux Développement, OTC AM, Euroainvest and l’Améliane) and the company’s management team. This third institutional financing round represents a milestone for the international growth and scaling of the business. Biom’Up welcomes on the board Dr. Karl Naegler (Gimv), Dr. Laurent Higueret (Bpifrance Large Venture) and Mr. Casper Breum (Lundbeckfond Ventures). The company also announces the arrival of Dr. Jan Ohrstrom as Chairman of the Board and Dr. William Spotnitz as medical director of the company. Both have an internationally recognized experience in the development and clinical evaluation of hemostatic products for surgery.
Therapeutic area: Medical devices
